#Germany #Sino Biological #Eschborn #EliteScience #European researchers

Sino Biological Unveils EliteScience VIP Partnership Program

On May 11, 2026, Sino Biological Europe GmbH announced the launch of its EliteScience VIP Partnership Program, aiming to support leading universities, research institutes, biotech companies, and pharmaceutical organizations across Europe. This exclusive initiative focuses on providing a premium service without an annual membership fee, designed specifically to alleviate research bottlenecks and expedite scientific discoveries.

The EliteScience program offers a variety of beneficial features centered around three core advantages: guaranteed priority production and delivery to minimize lead times, risk-free Contract Research Organization (CRO) services with a strict 'no results, no fees' policy, and priority access to complimentary reagent samples from an impressive catalog of over 77,000 products. Members of the program receive extensive additional support, which includes personalized technical assistance, 24-hour real-time responses from local specialists, price protection, and discounts on bulk orders.

Moreover, the program encompasses numerous academic initiatives and comprehensive research resources enabling researchers to improve the overall efficiency of their work and maximize their impact on publications. As a locally-operated initiative tailored to meet the specific research needs and procurement standards of the European research community, EliteScience seamlessly connects high-quality bioscience instruments with local research demand.

Dr. Bin Hu, the head of Sino Biological Europe GmbH, expressed, “EliteScience reflects our commitment to equip European researchers with top-notch resources and responsive support. This launch underscores our dedication to fostering long-term partnerships. By combining priority access, cost certainty, and personal service, we assist our partners in expediting their ideas into action.”

Background on Sino Biological

Founded in 2007, Sino Biological has established itself as a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and CRO services. The company serves researchers in over 90 countries, supporting fundamental research, drug discovery, vaccine development, and diagnostics through its extensive product portfolio, proprietary quality systems, and innovative research platforms.

Forward-Looking Statements

Certain statements in this document constitute 'forward-looking statements' in accordance with the Private Securities Litigation Reform Act. These statements rely on current management expectations from Sino Biological and are subject to uncertainties and changes in circumstances. Actual results could significantly differ from the outcomes contained in these statements due to various factors beyond Sino Biological’s control. Sino Biological does not undertake any obligation to update these forward-looking statements and does not intend to do so.

For media inquiries or collaboration opportunities, please contact Sino Biological, Inc. at email protected] or visit [www.sinobiological.com.